TM editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Last week’s MJAC event in Los Angeles attracted hundreds of cannabis businesses and several industry leaders.

While the event offered attendees a buffet of cannabis companies, some firms stood out above the rest. Isodiol International Inc. (ISOL.CN) (ISOLF) was one of the highlights of the entire conference and the company’s vast product line was on display.

Although we were aware of the company’s story, we left this event with an even more positive level of conviction. Isodiol offers a growing line of retail CBD products to suit customer lifestyles and preferences.

Isodiol Launches New Phytoceutical Division

Isodiol’s products are in high-demand and we expect this trend to continue as the company continues to expand its product line and enter new markets.

Today, Isodiol announced that it is launching a new Phytoceutical Division that will focus on cannabinoids and terpenes derived from non-cannabis sources. In the coming weeks, the company will provide additional information on the commercialization strategy of this division.

Isodiol will utilize proprietary extraction methods to ensure that the cannabinoids and terpenes are not denatured during the extraction process. The company said that this process will provide another superior product in the Isodiol offerings.

New Division Aims to Revolutionize the Cannabis Industry

Although marijuana is typically associated with getting high, the plant is much more than that. Scientists and researchers are just cracking the surface of medical marijuana and we have so much more to learn from this miracle plant.

Isodiol is focused on changing this thought process by launching this new division which will bring CBD based products to market that are not derived from the cannabis plant.

The discovery of cannabinoids in non-cannabis plants and the proprietary extraction methodology is a revolutionary development and provides an opportunity to manufacture and distribute medicinal and consumer products into markets that presently have restrictions on such products.

Isodiol International CEO Marcos Agramont said, “These highly innovative new products will open up our ability to sell into International markets much faster due to less regulations and restrictions surrounding our non-cannabis derived source of the CBD.”

A Long-Term Opportunity Growth Opportunity

Isodiol continues to expand its reach and has improved its position by securing strategic partners and successfully entering new markets. We are favorable on these moves and expect these developments to significantly support growth over the coming years.

One of the exciting developments in this area for Isodiol took place during June when the company started the approval process through Brazil’s Health Regulatory Agency to have its CBD products added to the list of approved imported CBD products.

In July, Canopy Growth and Isodiol signed a licensing agreement where Canopy can manufacture and distribute Pot-O-Coffee and Pot-O-Tea branded marijuana infused single serve K-Cup products in Canada and international markets that allow it.

A Story to Watch

We are favorable on Isodiol's multi-faceted growth strategy and expect to see continued growth for years to come. The company will benefit from a diverse strategy that is focused on both organic and inorganic growth opportunities.

Isodiol recently released an operational update regarding its subsidiary, Iso International that exceeded our expectations and we are favorable on these numbers. The company recently secured $25 million in convertible debenture financing with Alumnia Partners. We expect to see these funds be used to support growth initiatives and fund new opportunities.

Although many investors are focused on the publicly traded licensed medical cannabis producers, we think it is a mistake to take your eye off Isodiol International and believe it is a stock that needs to be watched.